Breaking News in Taiwan! Biotech giant Bora Pharmaceutical (6472-TW) makes waves with another strategic move! On the 16th, Bora announced its first U.S. acquisition—Upsher-Smith, a century-old pharmaceutical company, at a staggering $210 million. This landmark deal not only secures Bora's first manufacturing base in the U.S. but also significantly fortifies Bora's competitive edge in local sales operations.
 
Investment experts offer insights, cautioning on the historical turnover of Upsher-Smith in recent years, leading to an increased acquisition cost. The key lies in observing Bora's ability to leverage this investment, realizing profits, and maximizing the value of the remaining drug certificates over the medium to long term.
 
Stay tuned with #Globalbio for more updates!